Cardioplegic NDC 0338-0341

NDC codes

FDA NDC Directory

Product NDC (as listed)0338-0341Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00338-0341Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0338-0341-04	00338034104	14 BAG in 1 CARTON (0338-0341-04) / 1000 mL in 1 BAGMarketed from Apr 21, 2000

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Cardioplegic
Generic name (nonproprietary): calcium chloride, magnesium chloride, potassium chloride and sodium chloride
Active ingredients: Calcium chloride — 17.6 mg/100mLMagnesium chloride — 325.3 mg/100mLPotassium chloride — 119.3 mg/100mLSodium chloride — 643 mg/100mL
Dosage form: Solution
Route: Intra-arterial
Labeler: Baxter Healthcare Corporation
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 075323
Marketing start: Apr 21, 2000
Listing expires: Dec 31, 2027
Other FDA classes: Calcium (Chemical structure)Divalent (Chemical structure)Increased Coagulation Factor Activity (Physiologic effect)Increased Large Intestinal Motility (Physiologic effect)Increased Large Intestinal Motility (Physiologic effect)Increased Large Intestinal Motility (Physiologic effect)Inhibition Large Intestine Fluid/Electrolyte Absorption (Physiologic effect)Inhibition Large Intestine Fluid/Electrolyte Absorption (Physiologic effect)Inhibition Large Intestine Fluid/Electrolyte Absorption (Physiologic effect)Inhibition Small Intestine Fluid/Electrolyte Absorption (Physiologic effect)Magnesium Ion Exchange Activity (Mechanism)Osmotic Activity (Mechanism)Osmotic Activity (Mechanism)Osmotic Activity (Mechanism)Phosphate Chelating Activity (Mechanism)Potassium Compounds (Chemical structure)Stimulation Large Intestine Fluid/Electrolyte Secretion (Physiologic effect)
Identifiers: Product ID 0338-0341_f82c5f8a-ad36-4053-94e5-ec06322f9991SPL ID f82c5f8a-ad36-4053-94e5-ec06322f9991SPL set ID 1fd50ce5-2799-4c26-81da-02cf0578dd9eUNII M4I0D6VV5M, 02F3473H9O, 660YQ98I10, 451W47IQ8X
Pharmacologic class: Blood Coagulation Factor; Calculi Dissolution Agent; Osmotic Laxative; Phosphate Binder; Potassium Salt

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N400338034104 followed by a unit qualifier and the quantity

Package 00338-0341-04. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 11, 2020.

Indications (excerpt from the label)

INDICATIONS AND USAGE Baxter Cardioplegic Solution when suitably buffered in combination with ischemia and hypothermia is used to induce cardiac arrest during open heart surgery.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)